Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2007-02-05
2010-06-22
Davis, Brian J (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C564S084000, C564S097000, C514S602000, C514S605000
Reexamination Certificate
active
07741520
ABSTRACT:
Compounds and methods suppressing aromatase activity expression in cancer cells. Provided are compounds are those of formula I:wherein R1may be alkyl, cycloalkyl, haloalkyl, aryl, substituted aryl, haloaryl, alkoxy, alkylaryl, and arylalkyl; R2is H, alkyl, aryl, alkylaryl, arylalkyl, and cycloalkyl; R3, with the base nitrogen, forms an amide or sulfonamide; R4is selected from nitro, amine, amide, and benzamide; or a pharmaceutically acceptable salts thereof. Also provided are small molecule selective aromatase inhibitors having a molecular weight of less 500 g/mol. In some embodiments, the small molecule selective aromatase inhibitors described herein have a molecular weight of less than 450 g/mol. Also provided are methods for suppressing aromatase activity expression in cancer cells comprising the step of administering a pharmaceutically effective amount of a small molecule aromatase inhibitor to a subject in need of such treatment. In one embodiment, the cancer cells are breast cancer cells.
REFERENCES:
patent: 4026544 (1991-02-01), None
patent: 760212 (1934-02-01), None
patent: 58024138 (1983-02-01), None
patent: 02138168 (1990-05-01), None
patent: WO 2007/120379 (2007-10-01), None
Database CAPLUS on STN, Acc. No. 1970:43492, Jones et al., GB 1168105 (Oct. 22, 1969) (abstract).
International Search Report and Written Opinion in PCT/US07/03152, dated Dec. 17, 2007 (20 pages).
Adams et al., “Quinone imides. XXIII. Addition reactions of p-quinonedibenzimide and related compounds,” J. Am. Chem. Soc. (1952), vol. 74, pp. 5872-5876.
Berkade, et al., “Alkoxyaminonitrobenzenes. III. Nitration of 1-alkoxy-2-aminobenzenes and 1-alkoxy-2-acetamidobenzenes,” Recueil des Travaux Chimiques de Pays-Bas et de la Belgique (1947), vol. 66, pp. 374-382.
Jacobson, P., “Behavior of ethers of o-oxyazo compounds on reduction with stannous chloride and hydrochloric acid,” Ann. (1910), vol. 369, pp. 1-40.
Weigel, W., “Special substitution phenomena in the nitration of phenol ethers,” J. de Physiologie (Paris, 1946-1992) (1956), vol. 4, pp. 79-88.
Su et al., “Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition,” J. Med. Chem., 2006, 49, 1413-1419.
Su et al., “Synthesis and Biological Evaluation of Selective Aromatase Expression Regulators in Breast Cancer Cells,” J. Med. Chem. 2007, 50, 1635-1644.
Su et al., “Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition,” Steroids 73 (2008) 104-111.
Kellis, Jr. et al., “Purification and Characterization of Human Placental Aromatase Cytochrome P-450”, J. Biological Chemistry, vol. 262, No. 9, Mar. 25, 1987, pp. 4413-4420.
Diaz-Cruz et al., “Cyclooxygenase Inhibitors Suppress Aromatase Expression and Activity in Breast Cancer Cells”, J Clinical Endocrinology & Metabolism, 90(5) 2563-2570, 2005.
Baum et al. ATAC Trialists' Group, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359, 2131-2139.
Bergman, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000, 356, 881-887.
Brueggemeier, R. W.; Hackett, J. C.; Diaz-Cruz, E. S. “Aromatase inhibitors in the treatment of breast cancer” Endocr. ReV. 2005, 26, 331-345.
Chen, S. Aromatase and breast cancer. Frontiers Biosci. 1998, 3, 922-33.
Chen et al., Transcriptional regulation of aromatase expression in human breast tissue. J. Steroid Biochem. Mol. Biol. 2002, 83, 93-99.
Chen et al., Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue. J. Steroid Biochem. Mol. Biol. 2005, 95, 17-23.
Cignarella et al., Synthesis and pharmacological evaluation of derivatives structurally related to nimesulide. Eur. J. Med. Chem. 1996, 31, 359-364.
Hackett et al., Synthesis and characterization of azole isoflavone inhibitors of aromatase. Bioorg. Med. Chem. 2005, 13, 4063-4070.
Harada, N.; Honda, S. I.; Hatano, O. Aromatase inhibitors and enzyme stability. Endocr.-Rel. Cancer 1999, 6, 211-218.
Heshmati et al., Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J. Bone Miner. Res. 2002, 17, 172-178.
Hiroya et al., New synthetic method for indole-2-carboxylate and its application to the total synthesis of duocarmycin SA. Org. Lett. 2004, 6, 2953-2956.
Julemont et al., Spectral and crystallographic study of pyridinic analogues of nimesulide: determination of the active form of methanesulfonamides as COX-2 selective inhibitors. J. Med. Chem. 2002, 45, 5182-5185.
Kinoshita et al., Induction of Aromatase (CYP19) Expression in Breast Cancer Cells through a Nongenomic Action of Estrogen Receptor alpha. Cancer Res. 2003, 63, 3546-3455.
Richards et al., Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. J. Clin. Endocrinol. Metab. 2003, 88, 2810-2816.
Simpson, E. R. Aromatase: biologic relevance of tissue-specific expression. Semin. Reprod. Med. 2004, 22, 11-23.
Smith, I. E.; Dowsett, M. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 2003, 348, 2431-2442.
Zhao et al., Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes. Mol. Endocrinol. 1995, 9, 340-349.
Zhao et al., Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996, 137, 5739-5742.
Zhou et al., Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction (RT-PCR). J. Steroid Biochem. Mol. Biol. 1996, 59, 163-171.
Zhou et al., Identification of a promoter that controls aromatase expression in human breast cancer and adipose stromal cells. J. Biol. Chem. 1996, 271, 15191-15202.
Zhou et al., Gene regulation studies of aromatase expression in breast cancer and adipose stromal cells. J. Steroid Biochem. Mol. Biol. 1997, 61, 273-280.
American Cancer Society, Cancer Facts and Figures, 2005, American Cancer Society, Atlanta, 2005 , p. 1-28.
Natarajan, et al., “Adaptation of the diphenylamine (DPA) assay to a 96-well plate tissue culture format and comparison with the MTT assay”, Biotechniques, 1994, 17, 166-171.
Brueggemeier Robert W
Diaz-Cruz Edgar S
Landini Serena
Su Bin
Calfee Halter & Griswold LLP
Davis Brian J
The Ohio State University Research Foundation
LandOfFree
Sulfonanilide analogs as selective aromatase modulators (SAMs) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonanilide analogs as selective aromatase modulators (SAMs), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonanilide analogs as selective aromatase modulators (SAMs) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4197370